USA flag logo/image

An Official Website of the United States Government

Search


Download to spreadsheetPrint
Displaying 26 – 50 of 126 Awards
Company: ADVANCED RNA TECHNOLOGIES, LLC Agency/Program/Year/Phase: HHS / SBIR / 2011 / 1
Abstract: DESCRIPTION (provided by applicant): Introduction of small interfering RNAs (siRNAs) into cells with transfection reagents results in efficient gene silencing. Unfortunately, while siRNA-based functional genomics is widely used in vitro, the ability to apply this technology to… more
Company: TARGESON, INC. Agency/Program/Year/Phase: HHS / SBIR / 2011 / 2
Abstract: … in making gene therapy for kidney disease a reality. In the current proposal, we aim to develop a novel microbubble-based delivery vehicle for targeted TGF-2 gene therapy. We have developed a microbubble that can be conjugated with a payload of plasmid or siRNA, and… more
Company: LIFESPLICE PHARMA, LLC Agency/Program/Year/Phase: HHS / SBIR / 2011 / 1
Abstract: … and seizure susceptibility. Thus normalizing aberrant splicing represents a novel therapeutic strategy for preventing epileptogenesis. Splice modulating oligonucleotides (SMOs) have unique chemistries and distinct advantages over classic antisense oligonucleotides and siRNA,… more
Company: MUREX PHARMA Agency/Program/Year/Phase: HHS / SBIR / 2010 / 1
Abstract: … a tumor selective, non-immunogenic, RES-stealthed delivery vehicle. Stathmin 1 (STMN1), a critical regulator of tubulin polymerization/depolymerization, is overexpressed in 86% of our patients. We have constructed a unique bi-functional shRNA (bi-sh) with enhanced siRNA and… more
Company: B3 BIO, INC. Agency/Program/Year/Phase: HHS / SBIR / 2010 / 1
Abstract: … a drug to specific cells or tissues which could benefit from the drug activity , and avoid delivery of the drug to other areas where exposure to the drug could result in overt toxicity or other undesirable side effects. Functional RNAi molecules (e.g., shRNA, siRNA, RNAi,… more
Company: FALCON GENOMICS, INC. Agency/Program/Year/Phase: HHS / SBIR / 2010 / 1
Abstract: …, Inc. is developing the Cancer BioChip System (CBCS), a rapid, high-throughput, automated, and quantitative anchorage-independent growth assay for the personalized identi fication and validation of inhibitors of cancer cell growth. We will use silencing RNA (siRNA) or… more
Company: SILAGENE, INC. Agency/Program/Year/Phase: HHS / SBIR / 2010 / 1
Abstract: …method. Traditional approaches use an antisense oligonucleotide (ASO) designed to base pair with its complementary target mRNA leading to either degradation or impaired function of the mRNA. Current excitement has focused on RNAi that uses a distinct mechanism where siRNA… more
Company: RXI PHARMACEUTICALS CORPORATION Agency/Program/Year/Phase: HHS / SBIR / 2010 / 1
Abstract: DESCRIPTION (provided by applicant): Introduction of small interfering RNAs (siRNAs) into cells results in potent and specific gene silencing by RNA interference (RNAi). Unfortunately, while siRNA-based drugs represent a potentially significant therapeutic paradigm, the ability… more
Company: AM BIOTECHNOLOGIES, LLC Agency/Program/Year/Phase: HHS / SBIR / 2010 / 2
Abstract: DESCRIPTION (provided by applicant): New Reagents for Synthesis of High Potency siRNAs Abstract Since the discovery of short interfering RNA (siRNA) molecules in the late 1990s, siRNA technology has developed rapidly as a powerful tool for functional genom ic… more
Company: BCN BIOSCIENCES, LLC Agency/Program/Year/Phase: HHS / SBIR / 2010 / 1
Abstract: … cancer epithelial cell typ es, including human breast, colorectal and prostate cancer. Transfection studies showed that over- expression of EG-1 increases cellular proliferation in vitro and xenograft tumor growth in vivo. EG-1 inhibition, whether delivered via siRNA… more
Company: BOSTON BIOMEDICAL, INC. Agency/Program/Year/Phase: HHS / SBIR / 2010 / 1
Abstract: … (RNAi) promises to revolutionize medicine due to its unlimited potential to treat genetic, epigenetic and infectious diseases. RNAi mediated by synthetic short interfering RNA (siRN A) can theoretically be employed to target any disease gene. However, siRNA-mediated… more
Company: CELLECTA, INC. Agency/Program/Year/Phase: HHS / SBIR / 2010 / 2
Abstract: DESCRIPTION (provided by applicant): Despite rapid advances in elucidating the molecular basis of human diseases, an ostensibly more difficult post-genomic challenge is the functional annotation of disease-specific signaling pathways and integration of thi s information into the development of novel… more
Company: FUNCTIONAL GENETICS, INC. Agency/Program/Year/Phase: HHS / SBIR / 2010 / 2
Abstract: … efficacy against all HIV variants including drug-resistant viruses. In addition, by removing the selective pressure on the virus, host targeting circumvents drug resistance development. The identified targets in Phase I studies were validated using a siRNA approach and… more
Company: KEYSTONE NANO, INC. Agency/Program/Year/Phase: HHS / SBIR / 2010 / 1
Abstract: … during her lifetime at an estimated 12% and over 40,000 women dying from breast cancer each year (ACS). The development of NanoJackets containing both Indocyanine Green, a FDA-approved near infrared fluorophore, for fluorescent imaging based diagnosis, as well as siRNA directed… more
Company: Nanomaterial Innovation Ltd. Agency/Program/Year/Phase: HHS / SBIR / 2010 / 1
Abstract: 'This project will investigate transferrin (Tf) conjugated fluorescent nanoparticles loaded with an siRNA, LOR-1284, as a theranostic agent for acute myelogenous leukemia (AML). LOR-1284, a siRNA targeting the R2 subunit of ribonucleotide reductase (RNR),… more
Company: OpenCell Technologies Agency/Program/Year/Phase: HHS / SBIR / 2010 / 1
Abstract: …ffects induced in certain cell types during EAM treatment will facilitate the transition to a multichannel device. MIST development has the potential to greatly accelerate discovery of cancer therapi es by enabling simultaneous screening of synthetic small interfering RNA (… more
Company: LNKCHEMSOLUTIONS Agency/Program/Year/Phase: DOD / SBIR / 2010 / 1
Abstract: …article formulations and the University of Illinois Chicago with expertise in Acute Lung Injury (ALI) molecular biology and treatment modality development have teamed up to develop novel oral and inhalation formulation of targeted nanoparticles (NPs) containing siRNA and/or… more
Company: SIRNAOMICS, INC. Agency/Program/Year/Phase: HHS / SBIR / 2010 / 1
Abstract: …identification of crucial intracellular molecules and their associated signaling pathways as potential therapeutic targets. We are taking the advantage of RNA interference (RNAi) technology for development of the targeted therapeutics. Three small interfering RNA (siRNA)… more
Company: SIRNAOMICS, INC. Agency/Program/Year/Phase: HHS / SBIR / 2010 / 1
Abstract: …tic benefit. In early flu symptoms this target would be the lungs while systemic delivery will be required for later stages. Sirnaomics addresses these issues through proprietary nanoparticle delivery technologies that we have successfully used to demonstrate effective siRNA… more
Company: TRANSDERM, INC. Agency/Program/Year/Phase: HHS / SBIR / 2010 / 1
Abstract: … by applicant): Although RNA interference offers high potential as a novel therapeutic approach for treating skin disorders, delivery concerns have hampered their progression to the clinic. The most efficient and effective way to deliv er functionally-active siRNA is… more
Company: ZIRUS, INC. Agency/Program/Year/Phase: HHS / SBIR / 2009 / 1
Abstract: … available for the target. The importance of crystal structure is to facilitate drug discovery efforts that will begin in phase I and that will be the primary focus in phase II of the project. Using the indicator cell line U373 MAGI, which are readily transfectable with siRNA… more
Company: BIOO Scientific Agency/Program/Year/Phase: NSF / SBIR / 2009 / 2
Abstract: This award is funded under the American Recovery and Reinvestment Act of 2009 (Public Law 111-5). This Small Business Innovation Research (SBIR) Phase II project will develop technologies that optimize the use of RNA interference (RNAi) in animals. RNAi is an invaluable tool for characterizing gene… more
Company: SPHINGOGENE, INC. Agency/Program/Year/Phase: HHS / STTR / 2009 / 1
Abstract: … actions of Cer. Importantly, our recent studies identified AC as a negative prognostic factor in cancer therapy, since AC over-expression induces a more aggressive cancer phenotype which causes drug or radiation resistance. Reversal of AC expression utilizing siRNA or small… more
Company: EFFIGENE PHARMACEUTICALS, INC. Agency/Program/Year/Phase: HHS / STTR / 2009 / 1
Abstract: … base pairs. When applied to cells, siRNAs can effectively and specifically silence their target genes, called RNA interference (RNAi). RNAi has become attract ive tool for functional genomics and a potential class of molecules for human therapeutics. However, almost every … more
Company: GENESEGUES, INC. Agency/Program/Year/Phase: HHS / SBIR / 2009 / 1
Abstract: … RNAi oligonucleotides to defined liver target sites. Therefore, our proposed specific aims are to (1) determine utility and safety of s50 hepatocyte-targeted capsules for systemic delivery of double and single stranded RNAi oligonucleotides, using a published siRNA… more
Displaying 26 – 50 of 126 Awards
Narrow Your Search
By Agency
By Year
By Phase
By Program
By State
By Company Ownership
By Company
HELP FOR NARROW YOUR SEARCH

Search Options

There are several categories such as “By Agency”, “By Year”, “By State” etc. Select a checkbox within a category to refine your search results.

Each of your selections is listed in the “Narrow Search Filters” bar. You can uncheck these selections to remove them.


Search for Either Criteria

When you select multiple values within a category, the results will include values that match either of the selections. For example, selecting “2005” and “2007” in the “By Year” category will display results that include either 2005 OR 2007 in the results.


Narrowing the Search Results

You can refine your search results across categories. To narrow down your results, select multiple values across different categories. The results will only include values that match the selections across the categories. For example, selecting “2005” in the “By Year” category and “NASA” in the “By Agency” category will only display the results that contain both “2005” AND “NASA” in the results.